Survivin expression impacts prognostically on NSCLC but not SCLC

Rosato, Antonio; Menin, Chiara; Boldrin, Daniela; Santa, Silvia Dalla; Bonaldi, Laura; Scaini, Maria Chiara; Bianco, Paola Del; Zardo, Davide; Fassan, Matteo; Cappellesso, Rocco; Fassina, Ambrogio

doi:10.1016/j.lungcan.2012.11.004

Cited by 30 publications

(27 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survivin is an apoptosis-suppressing protein, promoting cell proliferation and inhibiting apoptosis [121,122]. Once Survivin is overexpressed in lung cancer, it may lead to antibody responses to this protein.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Autoantibodies in Lung Cancer: a Systematic Review and Meta-Analysis

Qin¹,

Zeng²,

Yang³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Recently, many studies have demonstrated that various tumor-associated autoantibodies have been detected in early stages of lung cancer. Therefore, we conducted a meta-analysis to comprehensively evaluate available evidence on the diagnostic value of autoantibodies against tumor-associated antigens in lung cancer. Methods: We systematically searched PubMed, Scopus, Web of Science and other databases through 23 March 2018. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2. We used the bivariate mixed-effect models to calculate pooled values of sensitivity, specificity, positive likelihood ratios, negative likelihood ratios, diagnostic odds ratios and associated 95% confidence intervals. Summary receiver operating characteristic (SROC) curves were used to summarize overall test performance. Deek’s funnel plot was used to detect publication bias. Results: Review of 468 candidate articles identified fifty-three articles with a total of 11,515 patients for qualitative review and meta-analysis. Pooled sensitivity, specificity and area under the SROC curve were as follows for tumor-associated autoantibodies against the following proteins: p53, 0.19, 0.98, 0.82; NY-ESO-1, 0.17, 0.98, 0.90; Survivin, 0.19, 0.99, 0.96; c-myc, 0.14, 0.98, 0.45; Cyclin B1, 0.18, 0.98, 0.91; GBU4-5, 0.07, 0.98, 0.91; CAGE, 0.14, 0.98, 0.90; p16, 0.08, 0.97, 0.91; SOX2, 0.14, 0.99, 0.93; and HuD, 0.17, 0.99, 0.82. Conclusion: Each tumor-associated autoantibody on its own showed excellent diagnostic specificity for lung cancer but inadequate sensitivity. Our results suggest that combinations or panels of tumor-associated autoantibodies may provide better sensitivity for diagnosing lung cancer, and the diagnostic accuracy of tumor-associated autoantibodies should be validated in more studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Autoantibodies in Lung Cancer: a Systematic Review and Meta-Analysis

Qin¹,

Zeng²,

Yang³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Survivin is an apoptosis-suppressing protein and its association with many types of cancer (including lung cancer) has been well documented 30, 31, 35, 36. However, few studies have investigated how SNP is related to EGFR mutations or prognosis in lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer

Liu¹,

Hsieh²,

Wu³

et al. 2016

Int. J. Med. Sci.

View full text Add to dashboard Cite

Survivin is an anti-apoptotic protein that is implicated in the regulation of apoptosis and cell cycle in various types of cancers. The current study explored the effect of survivin gene polymorphisms and EGFR mutations in non-small-cell lung carcinoma (NSCLC) patients. A total of 360 participants, including 291 adenocarcinoma lung cancer and 69 squamous cell carcinoma lung cancer patients, were selected for the analysis of three survivin genetic variants (survivin -31, +9194, and +9809) by using real-time PCR genotyping. The results indicated that GC+CC genotypes of survivin -31 were significant association with EGFR mutation in lung adenocarcinoma patients (adjusted odds ratio=3.498, 95% CI = 1.171-10.448; p<0.01). Moreover, The GC+CC genotypes of survivin -31 were associated with EGFR L858R mutation but not in exon 19 in-frame deletions. Furthermore, among patients in exon 19 in-frame deletions, those who have at least one polymorphic G allele of survivin -31 have an increased incidence to develop late-stage when compared with those patients homozygous for C/C (OR, 4.800; 95% CI, 1.305-17.658). In conclusion, our results showed that survivin genetic variants were related to EGFR mutation in lung adenocarcinoma patients and might contribute to pathological development to NSCLC.

show abstract

“…In colorectal cancer and breast cancer, patients with surviving-positive tumors had a decreased apoptotic index and worse survival rates than those with survivin-negative tumors [17, 27]. In addition, survivin expression was correlated with poor prognosis in esophageal cancer and non-small cell lung cancer [19, 20]. Survivin expression in pancreatic cancer tissues could also be a useful prognostic marker in patients with this disease [24, 25].…”

Section: Discussionmentioning

confidence: 99%

Survivin expression and serum levels in pancreatic cancer

et al. 2015

View full text Add to dashboard Cite

BackgroundSurvivin, an inhibitor of apoptosis, is overexpressed in pancreatic ductal adenocarcinoma (PDAC). Its expression is known to be associated with poor clinical outcome. However, to our knowledge, there has been no study to characterize its usefulness as a serum marker for human pancreatic cancer. Furthermore, the relation between survivin expression and the serum level of survivin has not been widely studied in PDAC. We performed this study to investigate the expression and serum level of survivin in PDAC and its clinical significance as a prognostic factor.MethodsWe performed immunohistochemical staining for survivin in formalin-fixed, paraffin-embedded blocks from 80 PDAC tissues. The serum level of survivin from the patients (n = 80) and age-matched healthy volunteers (n = 80) were analyzed by enzyme-linked immunosorbent assays (ELISAs) prior to surgical resection. Levels of expression were correlated with clinicopathological parameters.ResultsSerum survivin concentrations were significantly elevated in patients with PDAC when compared with healthy sera (P < 0.001). High serum survivin levels were significantly associated with perineural invasion, venous invasion, lymph node status (N stage), cell differentiation, and recurrence but not with the tumor size, age, gender of the patients, or tumor location. The median overall survival time of the group with normal serum survivin levels was longer than that of the group with elevated serum survivin. The independent factors associated with overall survival were advanced pancreatic cancer and elevated serum survivin level. Of the 80 cases of PDAC, 65 (81.25 %) were positive for survivin expression. There were significant associations between survivin expression and perineural invasion, venous invasion, and lymph node status. A significant difference in overall survival was associated with survivin expression.ConclusionsPatients with elevated serum survivin level and high survivin expression at diagnosis demonstrated a poor outcome. Detection of serum survivin or tissue survivin expression may predict the prognosis of patients with PDAC.

show abstract

Survivin expression impacts prognostically on NSCLC but not SCLC

Cited by 30 publications

References 51 publications

Diagnostic Value of Autoantibodies in Lung Cancer: a Systematic Review and Meta-Analysis

Diagnostic Value of Autoantibodies in Lung Cancer: a Systematic Review and Meta-Analysis

Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer

Survivin expression and serum levels in pancreatic cancer

Contact Info

Product

Resources

About